IDH2 and central nervous system cancer: As they attributed their results to DNA hypermethylation, they concluded their study by applying decitabine‐mediated hypomethylation to restore expression in IDH‐mutant glioma cells, suggesting its clinical potential to sensitize IDH‐mutant gliomas to NK cell‐mediated immune surveillance in patients with IDH‐mutant gliomas [66].